Novel therapeutic options in Acute Myeloid Leukemia  by Medinger, Michael et al.
Contents lists available at ScienceDirect
Leukemia Research Reports
journal homepage: www.elsevier.com/locate/lrr
Novel therapeutic options in Acute Myeloid Leukemia
Michael Medingera,b,⁎, Claudia Lengerkea, Jakob Passwega
a Divisions of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
b Divisions of Internal Medicine, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
A R T I C L E I N F O
Keywords:
Acute myeloid leukemia
Cellular therapies
Haplo-identical
Hematopoietic stem cell transplantation
Immunotherapy
Molecular targeted therapies
A B S T R A C T
Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease,
and its incidence is increasing as the population ages. Cytogenetic anomalies and mutation testing remain
important prognostic tools for tailoring treatment after induction therapy. Despite major advances in
understanding the genetic landscape of AML and its impact on the pathophysiology and biology of the disease,
as well as the rapid development of new drugs, standard treatment options have not experienced major changes
during the past three decades. Especially for patients with intermediate or high-risk AML, which often show
relapse. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the best chance for cure. Here we
review the state of the art therapy of AML, with special focus on new developments in immunotherapies and
cellular therapies including HSCT and particularly discuss the impact of new conditioning and haplo-identical
donor regimens for HSCT, post-transplant strategies for preventing and treating relapse, and emerging novel
therapeutic options.
1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous disorder char-
acterized by clonal expansion of blasts (myeloid progenitors) in the
bone marrow and peripheral blood. Formerly, AML had a very poor
prognosis; due to improvement in therapeutic regimens and supportive
care (e.g. anti-infective drugs, blood transfusion support), AML is now
cured in approximately 35–40% of patients younger with age younger
than 60 years [1]. For elderly patients ( > 60 years), the prognosis has
also improved, but overall remains adverse. Molecular screening plays
a major role in prognostic categorization and subsequent deﬁnition of
treatment strategies in AML. Cytogenetic abnormalities (e.g. deletions,
translocations), as detectable in approximately 50% of adult patients
with primary AML have long been associated with and recognized
cause [2]. Of these, for example alterations of chromosomes 5, 7, 11q23
and a complex karyotype (described as > 3 chromosomal abnormal-
ities) were shown to associate with poor response to therapy and
shorter overall survival (OS) while the presence of other cytogenetic
abnormalities like t(15;17)(q22;q12), t(8;21)(q22;q22) or inv(16)
(p13.1;q22) indicate longer disease remission and patient survival
[1,3]. In contrast, about 40–50% of all AML cases are cytogenetically
normal AML (CN-AML) [3]. CN-AMLs are considered to have an
intermediate risk for relapse. However, with respect to clinical outcome
substantial heterogeneity is observed in this group, which indicates
that further prognostic markers to be evaluated. More recently, the
identiﬁcation of mutations by gene sequencing has provided novel
prognostic and potentially therapeutical tools for patients with AML.
2. Prognosis/risk stratiﬁcation
Besides age and performance status, cytogenetic and molecular
aberrations are the most important tools to predict outcome in AML
[3]. In 2010, the European LeukemiaNet (ELN) classiﬁcation scheme
was created with the aim to standardize risk stratiﬁcation in adult AML
patients by including cytogenetic and known molecular abnormalities
[4]. Patients are classiﬁed into one of four risk groups: favorable,
intermediate 1, intermediate 2 and adverse (Table 1). Of note, acute
promyelocytic leukemia (APL) is excluded from the ELN classiﬁcation
and also not discussed in this review, as APL requires highly speciﬁc
prognostic, therapy and monitoring approaches that are largely diﬀer-
ent from those applied to other forms of AML.
3. AML therapies with curative intent
3.1. Induction Therapy
The backbone of anti-leukemic treatments with curative intent
builts on intensive induction chemotherapy regimens. The composition
of induction therapies has remained largely unchanged over more than
4 decades. For young adults (age < 60 years) and ﬁt elderly patients
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(especially if belonging to favorable prognostic groups according to
ELN criteria; see Table 1) the intensive anthracycline and cytarabine
regimen, “3+7”, induction therapy is standard of care [5]. The aim of
induction chemotherapy is to achieve complete morphologic remission
(CR) in curative intent [6]. Using standard induction with “3+7”,
higher morphologic CR rates are observed in young, de novo, versus
elderly ( > 60 years) AML patients (65–73% versus only 38–62%) [7,8].
The poorer CR rates observed in elderly versus younger patients are
due to more often observed patient co-morbidities that limit they dose-
intensity of applied therapies, but may also result from inherent
diﬀerences in disease biology, since secondary, therapy related and
high risk AML – according to molecular criteria – are overrepresented
in this group. Several trials have now shown that further enhancing the
dose of anthracycline (from 45 to 90 mg/m2) augments CR rates and
OS in both younger and 60–65 years old ﬁt adults, reinforcing the
notion that dose-intense chemotherapy is required to achieve cure [9].
However, enhanced toxicity is also observed with dose intensiﬁcation.
Thus, the grading of ﬁtness is important when deciding which
treatment strategy is most appropriate [10]. Besides assessment of
the AML risk group (see Table 1) the choice of intensive therapy for
elderly AML patients requires careful evaluation of the patient's ﬁtness,
vulnerability and frailty and should be assessed using standardized
geriatric assessment tools rather than based on calendaric age (re-
viewed in detail in [11]).
3.2. Consolidation therapy
The main aim of consolidation therapy is to prevent relapse by
eradicating minimal residual disease (MRD) still present in the bone
marrow after induction therapy [2]. For AML patients presenting with
molecular abnormalities, the depth of response after induction therapy
and during the course of the disease can be assessed at minimal
residual disease level using real-time polymerase chain reaction or
Next Generation Sequencing (NGS). Recent studies suggest that adding
molecular criteria to the morphological assessment is superior with
respect to prediction of imminent relapse, and therefore may be a
useful guide for treatment decisions [12,13]. There are two main
options for consolidation therapy: chemotherapy (including targeted
agents) and hematopoietic stem cell transplantation (HSCT) [14].
These strategies are used alone or most commonly in combination.
In younger adults ( < 60 years of age) with favorable risk AML, post
induction chemotherapy using intermediate-dose cytarabine 1.5 g/m2
twice daily on days 1, 3 and 5 given in three to four cycles is an eﬀective
and established regimen to prolong remission and improve survival
[5,15]. These patients are thus usually treated with chemotherapy
alone and transplantation is reserved only at relapse [5,15]. In the
HOVON/SAKK group, a third cycle of chemotherapy with mitoxan-
trone and etoposide is used as consolidation therapy [14]. In contrast,
patients suﬀering of intermediate or high-risk AML commonly receive
high-dose chemotherapy (as bridge to transplant) followed by HSCT;
overall, therapy is tailored depending on the aggressiveness of the
AML, but also the ﬁtness of the patient and the availability of a stem
cell donor.
3.2.1. Allogeneic hematopoietic stem cell transplantation
Particularly in ﬁt patients that suﬀer of intermediate or high-risk
AML and achieve CR after induction therapy, allogeneic HSCT remains
the most eﬀective long term treatment yielding cure in 50–60% of
patients [14,16–18]. Nevertheless, several patients never become
eligible for transplant because of co-morbidities, failure to reach CR
or lack of a suitable donor [1,2,16]. While waiting for transplant, it is
standard practice to give post induction chemotherapy to maintain CR
and keep the leukemia burden low. Eligibility for transplant is decided
upon based on pre-transplant performance status, co-morbidities and
current remission. The most widely recognized and validated tool for
assessing comorbidity includes the Hematopoietic Cell Transplantation
Comorbidity Index (HCT-CI) [19]. The higher the comorbidity index
score, the worse the clinical outcome. Improvements in supportive
care, increased donor options (haplo-identical donors and cord grafts)
and reduced intensity preparation regimens for HSCT have increased
the success of transplant in all age groups.
One of the most important treatment decisions in AML is to
estimate the beneﬁt/risk ratio of allogeneic HSCT for a given patient
in ﬁrst CR. Transplantation oﬀers the best means of preventing AML
recurrence, but remains associated with higher treatment-related
morbidity and mortality (TRM), especially in elderly patients. In
patients with favorable-risk AML, the relapse risk may be low enough
and the salvage rate high enough to postpone HSCT to second
remission. This strategy has been validated in several donor versus
no-donor studies [18,20]. In these studies, favorable patients (i.e.,
those with CBF-AML) from the no-donor group did as well as those
from the donor group, whereas all other patients appeared to beneﬁt
from undergoing allograft. One should keep in mind that patients in
these studies mostly underwent sibling donor myeloablative condition-
ing (MAC) transplantation and as such, the beneﬁt associated with
HSCT was only demonstrated for patients < 40 years of age. Based on
another donor versus no-donor analysis, patients with CN-AML and a
favorable genotype deﬁned as mutated CCAAT/enhancer-binding
protein alpha (CEBPA) or nucleophosmin 1 (NPM1) without Fms-
related tyrosine kinase 3-internal tandem duplications (FLT3-ITD)
were recently categorized in the favorable subgroup [4]. Because the
outcome after allogeneic HSCT from fully matched unrelated donors
appears to be similar compared with allogeneic HSCT from matched
related donors, all younger patients with intermediate- and unfavor-
able-risk AML are generally considered candidates for allogeneic HSCT
from sibling or fully-matched unrelated donors in cases of ﬁrst CR [16].
This HSCT beneﬁt/risk assessment, based on the European
LeukemiaNet (ELN) genetic classiﬁcation only [4], needs however to
be reconsidered in the near future. Alternative stem cell sources are
more widely used and are safer, as illustrated by post-transplant
administration of cyclophosphamide in haplo-identical HSCT [16,21].
In a recent survey of the EBMT (European Society for Blood and
Marrow Transplantation) by Passweg et al., a record number of 40.829
HSCT in 36.469 patients (15.765 allogeneic (43%), 20.704 autologous
(57%)) were reported by 656 centers in 47 countries. The trends in the
report included a continued growth in transplant activity, more so in
Eastern European countries than in the west; a continued increase in
the use of haplo-identical family donors (by 25%) and slower growth
for unrelated donor HSCT. The use of cord blood as a stem cell source
has decreased again in 2014 [16].
A recent study by Versluis et al. showed that allo-cHSCT might be
Table 1
European LeukemiaNet (ELN) risk group classification (adapted from Ref. [4]).
Genetic group Subsets
Favorable t(8;21), inv(16)
Mutated NPM1 without FLT3-ITD (normal karyotype)
Mutated CEBPA (normal karyotype)
Intermediate I Wild-type NPM1 (normal karyotypes)
FLT3-ITD (normal karyotype)
Intermediate II t(9;11); MLLT3-MLL
Cytogenetic abnormality not classified as favorable or adverse
Adverse inv(3) or t(3;3)
t(6;9)
t(v;11)
−5 or del (5q); −7; abnl (17p); complex karyotype
Abbreviations: abnl, abnormalities; CEBPA, CCAAT/enhancer-binding protein alpha;
del, deletion; FLT3-ITD, Fms-related tyrosine kinase 3-internal tandem duplications;
MLLT3-MLL, mixed lineage leukemia; NPM1, nucleophosmin 1.
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the preferred treatment approach in patients 60 years of age and older
with intermediate-risk and adverse-risk AML in ﬁrst CR [17]. 5-year
overall survival was 35% for patients who received an allo-HSCT, 21%
for those who received no additional post-remission therapy, and 26%
for patients who received either additional chemotherapy or auto-
HSCT. OS at 5 years was strongly aﬀected by the European
LeukemiaNET risk score, with patients in the favorable-risk group
(n=65) having better 5-year overall survival (56%) than those with
intermediate-risk (n=131; 23%) or adverse-risk (n=444; 13%) AML
[17].
In a further recent study of the EBMT, the outcomes of hypo-
methylating therapy (HMA) compared with conventional chemother-
apy (CC) pre-HSCT in 209 patients with advanced MDS was analyzed.
Median follow-up was 22.1 months and the median age of the group
was 57.6 years with 37% of the population aged > 60 years. The
majority of patients (59%) received reduced intensity conditioning and
34% and 27% had Int-2 and high IPSS scores, respectively. At time of
HSCT, 32% of patients did not achieve CR and 13% had primary
refractory disease. On univariate analysis outcomes at three years were
not signiﬁcantly diﬀerent between HMA and CC for OS, relapse free
survival (RFS), cumulative incidence of relapse (CIR) and non-relapse
mortality (NRM); OS (42 vs 35%), RFS (29 versus 31%), CIR (45
versus 40%) and NRM (26 versus 28%), respectively [22]. The authors
concluded that outcomes after HSCT are similar for patients receiving
HMA compared with those receiving CC, despite the higher proportion
of patients with primary refractory disease in the HMA group.
In a study by the HOVON/SAKK group, the best post-remission
therapy in patients aged 40–60 years was examined. They examined
the role of allo-HSCT (n=337) versus chemotherapy (n=271) or
autologous HSCT (auto-HSCT) (n=152) in 760 patients aged 40–60
years with AML in ﬁrst CR [14]. Patients receiving allo-HSCT showed
improved OS as compared with chemotherapy (respectively, 57 ± 3%
versus 40 ± 3% at 5 years, P < 0.001). Comparable OS was observed
following allo-HSCT and auto-HSCT in patients with intermediate-risk
AML (60 ± 4 versus 54 ± 5%). However, allo-HSCT was associated with
less relapse (hazard ratio (HR) 0.51, P < 0.001) and better RFS (HR
0.74, P=0.029) as compared with auto-HSCT in intermediate-risk
AMLs. Allo-HSCT was applied following myeloablative conditioning
(n=157) or reduced intensity conditioning (n=180), resulting in less
NRM, but comparable outcome with respect to OS, RFS and relapse.
Taken together, these results show that allo-HSCT is to be preferred
over chemotherapy as post-remission therapy in patients with inter-
mediate- and poor-risk AML aged 40–60 years, whereas auto-HSCT
remains a treatment option to be considered in patients with inter-
mediate-risk AML.
In a further study by Versluis et al., post-remission treatment in
patients with CN-AML in CR1 was examined [23]. Therapy consisted of
RIC allo-HSCT (n=68), MAC allo-HSCT (n=137), auto-HSCT (n=168)
or chemotherapy (n=148). Favorable OS was found for patients with
mutated NPM1 without FLT3-ITD (71 ± 4%). Outcome in patients with
a high FLT3-ITD allelic ratio appeared to be very poor with OS and
relapse-free survival (RFS) of 23 ± 8% and 12 ± 6%, respectively.
Patients with wild-type NPM1 without FLT3-ITD or with a low allelic
burden of FLT3-ITD were considered as intermediate-risk group
because of similar OS and RFS at 5 years, in which post remission
therapy by RIC allo-HSCT resulted in better OS and RFS as compared
with chemotherapy (hazard ratio (HR) 0.56, P=0.022 and HR 0.50,
P=0.004, respectively) or auto-HSCT (HR 0.60, P=0.046 and HR 0.60,
P=0.043, respectively). The lowest cumulative incidence of relapse (23
± 4%) was observed following MAC allo-HSCT. These results suggest
that allo-HSCT may be preferred in patients with molecularly inter-
mediate-risk CN-AML, while the choice of conditioning type may be
personalized according to risk for non-relapse mortality.
Taken together, these results highlight how genetic analyses
increasingly personalize the choice of anti-leukemic consolidation
therapies. While favorable-risk AML should be treated with chemother-
apy alone, addition of allo-HSCT improves outcome in high- and most
of the intermediate-risk AML, which overall are at higher risk for
relapse. In patients with intermediate-risk AML, auto-HSCT remains a
treatment option to be considered while further prognostic markers
stratifying this heterogeneous population are awaited.
3.2.2. Reduced intensity conditioning (RIC) versus myeloablative
conditioning (MAC)
A study by the EBMT examined the role of RIC conditioning versus
MAC to younger patients aged 40–60 years in CR1 [24]. Among 2974
patients, 1638 had MAC and 1336 RIC transplants. OS was higher in
patients with RIC with low-risk cytogenetics but not in the intermedi-
ate- or poor-risk AML. Relapse incidence was lower with MAC in poor-
and intermediate-risk AML. NRM was higher in MAC in all cytogenetic
risk groups. Multivariate analysis conﬁrmed a signiﬁcant leukemia-free
survival and OS advantage for RIC in low risk but no advantage of MAC
in intermediate- and poor-risk leukemia. In patients aged 40–60 years,
MAC has no advantage over RIC. They conﬁrmed lower relapse but
higher NRM risks with MAC. MAC is not superior in patients with
higher risk cytogenetics, but is inferior to RIC in the small cohort of
AML patients with low-risk cytogenetics. In sum, MAC conditioning
shows lower relapse rates but higher TRM and overall has no
advantage over RIC in patients aged 40–60 years, in spite of RIC
transplant recipients being generally of poorer AML risk category. In
the small cohort of patients with low-risk leukemia, RIC appears
superior. Interestingly, MAC failed to show superiority over RIC even
when AML patients of high-risk cytogenetics were analyzed separately.
3.2.3. Alternative donor transplantations
Haplo-identical HSCT provides an opportunity for nearly all
patients to beneﬁt from HSCT when a HLA genotypically matched
sibling is not available. Initial results with the use of mismatched
allografts led to limited enthusiasm due to graft-versus-host disease
(GvHD) and infectious complications resulting in unacceptable treat-
ment-related morbidity and mortality [16,21]. Recent advances with
eﬀective T-cell depletion, the use of ‘megadoses’ of stem cells, better
antimicrobial therapy and reduced intensity conditioning has signiﬁ-
cantly decreased the early transplant-related mortality and GvHD.
These modiﬁcations also enabled robust and prompt engraftment and
led to enhancing the therapeutic beneﬁts of haplo-identical transplan-
tation. Due to the high rates of graft failure and graft-versus-host
disease, haplo-identical transplant was not considered a feasible option
up until the late 20th century, when strategies such as “megadose stem
cell infusions” and post-transplantation immunosuppression with
cyclophosphamide showed the ability to overcome the HLA disparity
barrier and signiﬁcantly improve the rates of engraftment and reduce
the incidence and severity of GvHD. Newer technologies of graft
manipulation have also yielded the same eﬀects in addition to preser-
ving the anti-leukemic cells in the donor graft.
In a study by Ruggeri et al., the outcomes after unmanipulated
haplo-identical stem cell transplantation (haplo-HSCT) and after
unrelated cord blood transplantation (UCBT) were compared in
patients with high-risk acute leukemia without HLA-matched donor
[25]. UCBT was associated with delayed engraftment and higher graft
failure in both AML and ALL recipients. In multivariate analysis, UCBT
was associated with lower incidence of chronic GvHD both in the AML
group (hazard ratio (HR)=0.63, P=0.008) and in the ALL group
(HR=0.58, P=0.01). No signiﬁcant diﬀerences were noted between
haplo-HSCT and UCBT with respect to relapse incidence (HR=0.95,
P=0.76 for AML and HR=0.82, P=0.31 for ALL), non-relapse mortality
(HR=1.16, P=0.47 for AML and HR=1.23, P=0.23 for ALL) and
leukemia-free survival (HR 0.78, P=0.78 for AML and HR=1.00,
P=0.84 for ALL). There were no statistically diﬀerences on main
outcomes after unmanipulated haplo-HSCT and UCBT, and both
approaches are valid for acute leukemia patients lacking a HLA
matched donor. Thus, both strategies expand the donor pool for
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patients in need.
In a study by Mo et al., the impact of occurrence of chronic GvHD
(cGvHD) and its severity on transplantation outcomes in a consecutive
cohort of AML and MDS patients who received haplo-HSCT (n=324)
was investigated [26]. The cumulative incidence of relapse was
signiﬁcantly decreased in patients with cGVHD compared with the
non-cGvHD group (1 year: 3.2% versus 11.9%, P=0.002; 3 years: 6.0%
versus 16.3%, P=0.002), particularly in those with mild cGvHD. The
cumulative incidence of non-relapse mortality was comparable be-
tween patients with and without cGvHD. The probabilities of disease-
free survival (DFS) were signiﬁcantly better in patients with cGvHD
than in those in the non-cGvHD group (1 year: 90.5% versus 78.5%,
P=0.002; 3 years: 86.5% versus 71.5%, P < 0.001), particularly in those
with mild or moderate cGvHD; however, no signiﬁcant impact of severe
cGvHD on DFS was seen. Their ﬁndings highlight the close relationship
between cGvHD and the immune-mediated graft-versus-leukemia
(GvL) eﬀect in patients with AML and MDS receiving haplo-HSCT.
In a study by Kasamon et al., the eﬀect of age on non-myeloablative
(NMA) related HLA-haploidentical blood or marrow transplantation
(haplo-BMT) on outcomes in patients age 50-75 years was examined
[27]. A retrospective analysis was performed of 271 consecutive
patients with hematologic malignancies, age 50–75 years, who received
NMA, T-cell-replete haplo-BMT with high-dose post-transplantation
cyclophosphamide. The median age was 61 years, with 115 patients
(42%) age 50-59, 129 (48%) age 60–69, and 27 (10%) age 70–75 years.
Overall, 84% of patients had intermediate- or high-/very high-risk
disease. The 6-month probabilities of grade 3 or 4 acute GvHD and
NRM were 3% and 8%, respectively. Three-year progression-free
survival probabilities were 40% in acute myeloid leukemia (n=65),
39% in aggressive non-Hodgkin lymphoma (n=83), and 37% in
indolent or mantle-cell lymphoma (n=65). Older patient age was
associated with a signiﬁcantly higher risk of grade 2–4 acute GvHD
but not grade 3–4 acute or chronic GvHD. No statistically signiﬁcant
associations were found between older age (relative to age 50–59 years
or as a continuous variable) and NRM, relapse, or survival. They
concluded that NMA haplo-BMT with post-transplantation cyclopho-
sphamide has encouraging safety and survival outcomes in patients age
50-75 years which support consideration of this approach in elderly
patients.
Taken together, the emergence of new transplant strategies invol-
ving reduced conditioning regimens but also alternative stem cell
sources and post-transplant in vivo graft modulation promise to make
this therapy (and thus cure) applicable to a wider group of patients
(including elderly patients with co-morbidities and/or high-risk dis-
ease).
4. Alternative treatment strategies
4.1. The use of hypomethylating agents
Hypomethylating agents including decitabine and azacitidine seems
to be beneﬁcial in older AML patients, not ﬁt for intensive induction
therapy, especially, those harboring complex karyotype without NPM1
mutations [28–32]. Both agents, commonly used to treat MDS, have
activity in AML as initial induction therapy and in the relapsed setting.
Several phase II and III studies using azacitidine and decitabine have
been conducted [28–32].
In a randomized phase III trial by Dombret et al., azacitidine
eﬃcacy and safety was compared with conventional care regimens
(CCRs; standard induction chemotherapy, low-dose ara-c, or suppor-
tive care only) in 488 patients age ≥65 years with newly diagnosed
AML with > 30% bone marrow blasts [29]. Median OS was increased
with azacitidine versus CCR: 10.4 months versus 6.5 months. One-year
survival rates with azacitidine and CCR were 46.5% and 34.2%,
respectively. Univariate analysis showed favorable trends for azaciti-
dine compared with CCR across all subgroups deﬁned by baseline
demographic and disease features.
However, in the randomized AML-AZA trial by Müller-Tidow et al.,
the eﬃcacy of azacitidine applied before each cycle of intensive
chemotherapy with chemotherapy alone in older patients with un-
treated AML was evaluated [30]. In total, 214 patients with a median
age of 70 years were randomized to azacitidine/chemotherapy (arm-A)
or chemotherapy (arm-B). Adverse events were more frequent in arm-
A (15.44) versus 13.52 in arm-B, (P=0.26), but early death rates did
not diﬀer signiﬁcantly (30-d mortality: 6% versus 5%, P=0.76). Median
OS was 15 months for patients in arm-A compared with 21 months in
arm-B (P=0.35). Azacitidine added to standard chemotherapy in-
creases toxicity in older patients with AML, but provides no additional
beneﬁt for unselected patients.
Regarding older patients, a phase II study examined azacitidine in
elderly or frail patients with AML [31]. Azacitidine was administered
100 mg/m2, 5 of 28 days for up to six cycles. Altogether 45 patients
were accrued. Best response was complete response/complete response
with incomplete recovery of neutrophils and/or platelets (CR/CRi) in
eight (18%), 0 (0%) partial response (PR), seven (16%) hematologic
improvement, 17 (38%) stable disease. Three non-responding patients
stopped treatment after six cycles, 31 patients stopped early and 11
patients continued treatment for 8–21 cycles. Adverse events (grade ≥
III) were infections (n =13), febrile neutropenia (n =8), thrombocyto-
penia (n =7), dyspnea (p=6), bleeding (n =5) and anemia (n =4).
Median overall survival was 6 months. The authors concluded that
azacitidine is feasible for elderly or frail patients with AML in an
outpatient setting with moderate, mainly hematologic, toxicity and
response in a proportion of patients, although the primary objective
was not reached.
Recently, a new oral formulations of azacitidine was developed; CC-
486. The randomized placebo-controlled phase III trial (AZA-MDS-
003) examines eﬃcacy and safety of CC-486 in patients with low-risk
MDS (following IPSS; international prognostic scoring system) [32].
5. Targeted therapies: the new kids on the block
The recognition of speciﬁc mutations as genetic drivers or facil-
itators of AML has led to the development of new inhibitors and
targeted treatment options. New promising drug candidates have been
tested in clinical studies, for their ability to control disease as single
agents or to improve cure rates and overall survival when combined
with standard chemotherapy regimens (see Table 2). During the last
decade, several studies have shown that the presence or absence of
speciﬁc gene mutations and/or changes in gene expression can further
classify AML cases and have an eﬀect on the patients’ prognosis [2–
5,33–35]. This is particularly relevant for patients with cytogenetically
normal AML (CN-AML). In a very recent article by Papaemmanuil
et al. the role of mutations and its correlation with pathophysiology was
examined in a large cohort of 1540 AML patients [35]. They identiﬁed
5234 driver mutations across 76 genes or genomic regions, with 2 or
more drivers identiﬁed in 86% of the patients. Patterns of co-mutation
compartmentalized the cohort into 11 classes, each with distinct
diagnostic features and clinical outcomes. In addition to currently
deﬁned AML subgroups, three heterogeneous genomic categories
emerged: AML with mutations in genes encoding chromatin,
RNAsplicing regulators, or both (in 18% of patients); AML with TP53
mutations, chromosomal aneuploidies, or both (in 13%); and, provi-
sionally, AML with IDH2R172 mutations (in 1%). Patients with
chromatin–spliceosome and TP53–aneuploidy AML had poor out-
comes, with the various class-deﬁning mutations contributing inde-
pendently and additively to the outcome. They found gene–gene
interactions which were especially pronounced for NPM1-mutated
AML, in which patterns of co-mutation identiﬁed groups with a
favorable or adverse prognosis [35]. In our review, we will focus on
three relevant AML mutations.
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5.1. Fms-like tyrosine kinase 3 (FLT3) mutations
FLT3 is a class III family receptor tyrosine kinase acting as a
cytokine receptor for FLT3 ligand. FLT3 was found to be strongly
expressed in hematopoietic stem cells with important roles in cell
survival and proliferation [5,36]. FLT3 mutations are among the most
frequent mutations observed in AML and two types are distinguished.
Internal tandem duplications of FLT3 are identiﬁed in about 20% of
patients with AML, and in 28–34% of those with CN-AML; in the latter
instance they predict poor outcome [2–5,37]. These mutations are
mostly located in the juxtamembrane domain. In 28% of cases, they are
found in the tyrosine kinase domain, and predict a particularly poor
prognosis. The internal tandem duplications in FLT3 constitutively
activate the tyrosine kinase by interfering with the auto-inhibitory
function of the juxtamembrane domain and lead to enhanced RAS,
MAPK, and STAT5 signaling [5,37–39]. Both types of mutations
constitutively activate FLT3 signaling, promoting blast proliferation
[5,37,38]. This eﬀect on prognosis is modulated by the mutated to
wildtype allele ratio, with inferior outcome in the presence of a higher
load of internal tandem duplications in FLT3. Evidence is emerging
that AML patients with these mutations beneﬁt from allo- HSCT in
CR1, which is recommended for this group [4]. Furthermore, FLT3-
ITD mutations have been associated with increased risk of relapse,
while the prognostic relevance of FLT3-TKD mutations is controversial
[39]. The degree to which FLT3-ITD is a biomarker associated with
poor outcome is determined by the binding site and FLT3-ITD allelic
burden [37,39,40]. Studies have shown that non-JM ITD are worse
than JM domain ITD and higher mutant to wild-type allelic ratios were
signiﬁcantly associated with lower CR rates [39,40]. Currently, tyrosine
kinase inhibitors (TKI) are being tested in FLT3 mutated AML patients.
Unfortunately, when used alone, TKIs showed only a transient reduc-
tion of blasts, and even if initially eﬀective, subsequent acquisition of
secondary mutations induces resistance over time [41]. Several FLT3
small molecule inhibitors have been developed with mixed results. First
generation drugs include multi-kinase inhibitors such as midostaurin,
lestaurtinib, tandutinib sunitinib and sorafenib. When used as single
agents they have limited anti-leukemia activity mostly showing only
transient reduction of blood and bone marrow blasts and increased
toxicity [42]. In a randomized trial of 224 patients with FLT3 mutated
AML in ﬁrst relapse lestaurtinib did not increase the response rate or
prolong survival [43]. Single agent use with midostantrum, tandutinib
and KW2449 in phase I/II trials were also not clinically eﬀective [44–
46]. Combination therapy using FLT3 inhibitors with chemotherapy
have also been conducted. Serve et al. reported a randomized trial of
201 newly diagnosed older AML patients, using the addition of
sorafenib to induction and consolidation therapy. Unfortunately,
sorafenib did not improve outcomes and patients did worse in the
sorafenib arm due to higher treatment-related mortality and lower CR
rates [47]. A recent phase II study of sorafenib in combination with 5-
azacitadine in relapsed/refractory FLT3-ITD mutant AML demon-
strated a response rate of 46%, mostly consisting of CR or CR with
incomplete count recovery [48]. Sunitinib added to induction and
consolidation chemotherapy in older patients with AML and FLT3
activating mutations showed some eﬀectiveness with CR rates 53% (8/
15) and 71% (5/7) for patients with FLT3-ITD and FLT3-TKD
mutations, respectively. The 13 patients who achieved CR went on to
be consolidated with high dose cytarabine and 7/13 received sunitinib
maintenance. The median OS in this study was 18.8 months [49]. In a
recent randomized, double-blind, placebo-controlled, phase 2 study by
Röllig et al., the eﬃcacy and tolerability of sorafenib versus placebo in
addition to standard chemotherapy in patients with AML aged 60 years
or younger was examined [50]. 267 patients were included in the
primary analysis (placebo, n=133; sorafenib, n=134). With a median
follow-up of 36 months, median event-free survival was 9 months in
the placebo group versus 21 months in the sorafenib group, corre-
sponding to a 3-year event-free survival of 22% in the placebo group
versus 40% in the sorafenib group. Midostaurin (PKC-412) is a
moderately potent inhibitor of FLT3-ITD and FLT3 tyrosine kinase
domain (TKD) mutations and inhibits other kinases such as c-KIT,
PDGFR-b, VEGFR-2, and protein kinase C [51]. At the 2015 American
Society of Hematology (ASH) Annual Meeting, the RATIFY study, an
international randomized phase III study of midostaurin or placebo in
Table 2
Mutational landscape in Acute myeloid leukemia.
Mutation Frequency in CN-AML Mode of action Prognosis Target “drugable” Drugs
NPM1 30–45% Nucleolar component favorable – –
DNMT3A 34% De no DNA methylation inconclusive – –
FLT3-ITD 28–34% Receptor tyrosine kinase for Flt3 ligand Unfavorable tyrosine kinase inhibitors e.g. sorafenib,
midostaurin
quizartinib
FLT3-TKD 11–14% Receptor tyrosine kinase for Flt3 ligand Neutral – –
IDH1 and
IDH2
15–30% Conversion of isocitrate to α-ketoglutarate Favorable e.g. AG−221
TET2 10% Conversion of 5 methylcytosine to 5-hydroxy-methylcytosine,
mediating demethylation
Inconclusive – –
ASXL1 5–16% Epigenetic regulation by interaction with PRC2 Unfavorable – –
CEBPA 10–18% Haemopoietic transcription factor Favorable – –
RAS 25% NRAS, 15% G-protein associated with receptor tyrosine kinases Neutral RAS
downstreamKRAS
Inhibitors
KIT 20–30% of CBF Receptor tyrosine kinase for stem cell factor Unfavorable Kinase inhibitors E.g. imatinib
dasatinibAML
MLL-PTD 5–10% 20–30% of CBF Unfavorable – –
AML
RUNX1 5–13% Haemopoietic transcription factor Unavorable
Abbreviations: ASXL1, Additional sex comb like 1; CBF, core-binding factor; CEBPA, CCAAT/enhancer-binding protein alpha; CN-AML; cytogenetically normal acute myeloid leukemia;
DNMT3A, DNA methyl-transferase 3 A; FLT3-ITD, Fms-related tyrosine kinase 3-internal tandem duplications; FLT3-TKD, Fms-related tyrosine kinase 3-tyrosine kinase domain;
IDH1 and IDH2, Isocitrate dehydrogenase 1,2; KIT, CD117; MLL-PTD, mixed lineage leukemia partial tandem duplication; NPM1, nucleophosmin 1; PRC2, polycomb repressive
complex 2; RAS, RAS viral (v-ras) oncogene homologue; RUNX1, Runt-related transcription factor 1; TET2, Ten-11 translocation 2.
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combination with induction and consolidation chemotherapy, was
presented. The outcomes showed improved 5-year OS in the mid-
ostaurin arm (51.4% vs. 44.2%), regardless of whether patients were
censored at the time of stem cell transplant, despite no diﬀerence in the
rates of CR at 60 days [52]. The superiority of midostaurin/chemother-
apy over placebo/chemotherapy was consistent regardless of allelic
burden (high versus low), FLT3-ITD, or FLT3-TKD. Patients receiving
midostaurin had an increased frequency of grade 3–4 desquamating
rash. The overall survival beneﬁt in combination with the favorable
toxicity proﬁle makes midostaurin in combination with induction and
consolidation chemotherapy the new standard of care for patients with
FLT3-mutated AML.
Second generation agents, promising to have better potency and
less side eﬀects include quizartinib and crenolanib are still undergoing
clinical investigation. Drug resistance has become the major challenge
in treating patients with a single FLT3 inhibitor. The point mutations
identiﬁed which lead to resistance include N676, F691, and D835
within the kinase domain of FLT3-ITD [53]. The novel FLT3 inhibitors,
G-749 and ASP2215 (gilteritinib; active against both FLT3 ITD and
D835 mutations), have recently been shown to provide sustained
inhibition of FLT3 phosphorylation and increased ability to overcome
drug resistance in pre-clinical trials but further studies are needed to
determine if it will have clinical eﬃcacy [54,55].
5.2. Nucleophosmin 1 (NPM1) mutations
The nucleolar protein nucleophosmin 1 is involved in many cellular
functions such as ribosome biogenesis, DNA repair, and regulation of
apoptosis. Mutations result in aberrant localisation of the protein to the
cytosol; an N-terminal nucleolar localisation signal is disrupted and an
export signal created instead. Mutations in the gene NPM1 are among
the most common genetic changes in AML (occurring in 25–35% of
patients), especially in CN-AML (present in 45–64%) [56,57]. In the
absence of FLT3-ITD mutations, NPM1 mutations are associated with
improved outcome for patients with CN-AML, even in those older than
60 years. Current European LeukemiaNet recommendations for diag-
nosis and treatment of AML class NPM1-mutated, FLT3 wild-type CN-
AML as a favorable risk condition and discourage allogeneic HSCT in
CR1 [4]. The reason for improved survival remains unclear however it
has been found that NPM1 mutations have been associated with
chemosensitivity to intensive chemotherapy in both young and old
patients, which may account for improved outcome [58]. NPM1
mutations are associated with other recurrent genetic abnormalities
such as +8, DNMT3A mutations, FLT3-ITD (40% of the time), FLT3-
TKD (10–15%) and IDH mutations (25% of time) [59,60].
5.3. Isocitrate Dehydrogenase (IDH) mutations
Mutations of the isocitrate dehydrogenase (IDH) 1 and 2 gene are
gain-of-function mutations which cause loss of the physiologic enzyme
function and create a novel ability of the enzymes to convert α-
ketoglutarate into 2-hydroxyglutarate. Speciﬁcally recurrent mutations
aﬀecting the highly conserved arginine (R) residue at codon 132
(R132) of IDH1 and at codons R140 and R172 of IDH2 have been
identiﬁed in 15–20% of all AML and 25–30% of patients with CN-AML
[34,61,62]. IDH mutations are oncogenic. They are found more
frequently in older patients [60]. IDH mutations, in particular IDH1,
are associated with lower DFS and OS in CN-AML cases with NPM1
mutations and wild type FLT3 [60,62]. Orally available, selective,
potent inhibitors of mutated IDH are currently being tested in Phase
I and II studies in AML with promising results [63]. Mutant IDH
enzymes acquire neomorphic activity and catalyze the conversion of
alpha-ketoglutarate into beta-hydroxygutarate (2-HG). Increased in-
tracellular 2-HG causes inhibition of TET enzymes and subsequent
arrest in myeloblast maturation [64–66]. Inhibitors of mutant IDH1
and mutant IDH2 are currently in phase I clinical trials
(NCT02381886, NCT01915498, and NCT02074839). Interim results
of a phase I/II study of the IDH2 inhibitor AG-221 (Agios/Celgene),
presented at the 2015 ASH Annual Meeting, demonstrated an overall
response rate of 37% among 159 patients with relapsed/refractory
AML with a composite complete remission of 27%. Duration of
response was 6.9 months [67]. Similarly, a phase I study of the IDH1
inhibitor AG-120 demonstrated an overall response rate of 35%, with a
composite complete remission rate of 33% [68]. Accrual has started on
a phase I study exploring the safety of combining AG-120 and AG-221
with both induction and consolidation chemotherapy and with 5-
azacitidine (NCT02632708 and NCT0267792).
6. Strategies for prevention and treatment of relapse
6.1. Immunotherapy
Immunotherapy for AML involves two diﬀerent therapeutic op-
tions: allo-HSCT (as reviewed above) and non-transplant treatments.
Immunotherapy approaches are often ﬁrst examined in patients who
have received allo-HSCT either to prevent or treat relapsing leukemia
[69]. While many immunotherapy strategies apply in or outside the
context of HSCT, the alloimmune graft-versus-leukemia (GvL) eﬀect is
important mediating cure. Indeed, allo-HSCT is still the only un-
doubted immune-based approach to cure leukemias resistant to
chemotherapy. The GvL eﬀect is mediated by both T cells and NK cells
[70,71]. While the stem-cell source (bone marrow, peripheral blood or
cord blood), degree of compatibility (identical twin, matched related,
matched unrelated and haplotype matched related donors) and trans-
plant approach (conditioning regimen and method of GvHD preven-
tion) can all inﬂuence outcome, the major factor determining the
survival and cure of AML is the remission status of the leukemia before
HSCT. Patients of standard-risk AML transplanted in CR1 have a
relapse rate of 20% or less; those in CR2 or subsequent remission have
an intermediate relapse risk of around 40%, while patients trans-
planted with overt disease either because of refractoriness to induction
therapy or uncontrolled relapse had a signiﬁcantly higher relapse risk
around 60% [69,70]. Despite numerous strategies manipulating the
transplant schedule to decrease relapse rates, these statistics have not
changed signiﬁcantly for over 40 years. This is in part due to the fact
that approaches that boost the GvL eﬀect are constrained by the
increase in morbidity and mortality from GvHD, and increased
ablation of leukemia by radiation and chemotherapy is limited by
increased mortality from nonrelapse causes. In addition, despite many
innovative attempts to control relapsed disease by boosting GvL, AML
cells can display or develop resistance to immune control. Relapse of
AML after HSCT is largely incurable and still carries a dismal
prognosis. The standard treatment of AML relapsed after HSCT is
chemotherapy, targeted drugs or hypomethylating agents in combina-
tion or followed by donor lymphocytes infusion (DLI).
6.1.1. Immunotherapy after HSCT: GvL, GvHD and Donor
lymphocytes infusion (DLI)
The full realization that GvL was a major contributor to the curative
eﬀect of allo-HSCT in the 1980 s led logically to the use of DLI to
prevent or treat relapse after transplant [72]. Unfortunately, the ﬁrst
demonstrations that DLI could achieve durable remissions in relapsed
CML were not borne out in AML and MDS where the therapeutic
beneﬁt of DLI is at best modest.
New developments in immunological understanding and ability to
manipulate immune cells are beginning to break the impass of GvL
linked to GvHD and improve the curative potential of allo-HSCT.
Relapse after HSCT with its extremely poor prognosis has become a
proving ground for the most innovative and experimental immunother-
apy, appropriate for such desperate circumstances. Thus many of the
strategies described below were initially developed or have only been
applied in the context of HSCT. However, the application of novel
M. Medinger et al. Leukemia Research Reports 6 (2016) 39–49
44
immunotherapy outside the context of HSCT is now ongoing. These
new strategies can be categorized as: (1) lymphocyte products to
deliver enhanced and speciﬁc anti-leukemic cytotoxic (cell therapy);
(2) immunomodulatory drugs; and (3) treatments to boost immunity
and enhance leukemia's susceptibility to immune system [69].
For example, Treg-depleted DLI has been used to augment GvL
[69]. Manipulation of Tregs in the context of HSCT (both in the graft
and in the host after transplantation) has two implications: depletion of
Tregs may enhance GvL, but enrichment of Tregs is eﬃcacious for
prevention and treatment of GvHD [73]. Further studies are required
to identify the optimal therapeutic approach involving Treg-mediated
pathways to achieve a ﬁne balance between GvL and GvHD.
6.1.1.1. Modulation of post-transplant immunological responses to
prevent or treat AML relapse. With improvement in transplant-
related mortality over the past decades, the prevention of post-
transplant relapse becomes important. The early post-transplant
setting is uniquely advantageous for immunotherapy to work, where
the leukemic burden is low and anti-leukemia lymphocytes have the
chance to expand in the post-transplant immune milieu and
lymphodepleted environment [74]. Furthermore, it is possible to
adoptively transfer donor cells that are not exhausted or tolerated as
a part of transplant course (as DLI, see above).
However, leukemic cells may perform immune escape and patients
thus suﬀer from severe GvHD without beneﬁting from corresponding
GvL eﬀects. The investigation of mechanisms of immune-sensitization
of leukemic cells and drugs provoking such responses has thus emerged
as a promising research avenue. For example, post-transplant treat-
ment with sorafenib was shown to potentiate GvL in AML patients
treated with HSCT [75]. Furthermore, azacitidine has been reported to
either prevent or delay hematological relapse when applied to MRD
positive post-HSCT patients [76,77]. Prophylactic usage of low-dose
azacitidine for patients with high-risk MDS/AML post-transplant is
safe and may improve event-free survival and overall survival [76,78].
6.1.2. Cellular therapies
6.1.2.1. Chimeric antigen receptor modiﬁed T cells (CAR-T). The
remarkable therapeutic successes using CAR-modiﬁed T cells to treat
leukemia have attracted wide enthusiasm for CAR cell therapy and T-
cell therapy in general. The principle is to insert a T-cell receptor
(TCR)/costimulatory molecule/linker/antigen binding domain derived
from the fusion of the variable regions of the heavy and light chains of
immunoglobulins speciﬁc for a leukemia surface antigen (e.g. anti
CD19) construct into T cells. The antibody binds surface molecules on
the leukemia, triggers TCR activation and directs T-cell cytotoxicity to
the leukemia. Initial reports of remissions achieved in ALL and chronic
lymphocytic leukemia (CLL) by Porter and colleagues [79,80] have led
many investigators to adopt and further reﬁne this technology.
There has been considerable interest in using CAR technology to
target myeloid leukemias. CD123 is overexpressed by AML but it is also
well-expressed on normal myeloid cells, although expression on
hematopoietic stem and progenitor cells is weaker [81–83].
Nevertheless the risk of marrow ablation limits the application of
anti-myeloid leukemia CAR cells to pretransplant conditioning where
healthy stem cells can be infused after ablation of the CAR cells. While
CAR cells have alerted the hematology community to the potency of T-
cell-based therapy and stimulated considerable interest of pharmaceu-
tical companies in developing cell therapy, they have some important
limitations. Most importantly, their use in myeloid leukemia is
restricted by the lack of antigens that are uniquely expressed by the
leukemic cell as compared to their counterparts, the hematopoietic
stem/progenitor cells.
6.1.2.2. NK cell therapies. It is now feasible to expand NK cells ex vivo
for cell therapy. NK cells can be selected with magnetic beads coated
with CD56 from an apheresis collection and can be expanded with
Epstein–Barr virus (EBV) transformed B cell lines or K562 cell lines
expressing costimulatory molecules and membrane-bound IL-15 or IL-
21 [84,85].
In a study by Meyer-Monard et al., the production of NK cells under
good manufacturing practice (GMP) conditions in a suﬃcient number
was examined [86]. Twenty-four apheresis procedures and subsequent
NK-cell enrichment from 14 haplo-identical donors were performed.
NK-cell enrichment was performed using a GMP suitable immuno-
magnetic procedure. Factors inﬂuencing the NK-cell recovery, purity,
and NK-cell dose were analyzed. A median number of 4.9×108 NK cells
were obtained and median NK-cell recovery was 58%. Median T-cell
depletion was 4.32 log. The absolute NK-cell number in the ﬁnal
product after processing signiﬁcantly correlated with the preharvest
NK-cell content of the peripheral blood (p=0.002; r =0.867). Early
trials show that NK cell infusions are without the risk of GvHD. In a
pilot study by Passweg et al., the feasibility of natural killer cell
puriﬁcation and infusion (NK-DLI) in patients after haplo-identical
HSCT was examined [87]. The aim was to obtain ≥1.0×107/kg CD56+/
CD3- NK cells and < 1.0×105/kg CD3+ T cells. Mononuclear cells were
collected by 10 l leukapheresis. A two-step ex vivo procedure was used
to purify NK cells, using an immunomagnetic T-cell depletion, followed
by NK-cell enrichment. Five patients with high-risk myeloid malig-
nancies were included, presenting 3–12 months after a haplo-identical
HSCT with mixed chimerism (3), impending graft failure (1) or early
relapse (1). The puriﬁed product contained a median of 1.61×107/kg
(range 0.21–2.2) NK cells and 0.29×105/kg (0.11–1.1) T cells. A purity
of NK cells of 97% (78−99), a recovery of 35.5% (13−75), and a T-cell
depletion of 3.55 log (2.9–4.5) was achieved. Infusions were well
tolerated and none of the patients developed GvHD. They observed
an increase in donor chimerism in 2/5, stable mixed chimerism,
decreasing chimerism and relapse of AML in one patient each.
Selection of NK-DLI is technically feasible. NK cells are well tolerated
when used as adoptive immunotherapy in recipients of haplo-identical
HSCT. Two recent uncontrolled studies suggest that NK cells may be
eﬃcacious in preventing relapse or treating refractory AML [88,89].
After lymphodepleting treatment with cyclophosphamide and ﬂudar-
abine, haploi-dentical NK cells were administered to children with
AML in ﬁrst CR. The 2 year event-free survival was 100% [89]. A
similar lymphodepletion/haploidentical NK cell infusion study in 19
adults with refractory AML achieved 5 complete remissions [88]. These
results are preliminary and need further validation.
6.1.2.3. Immune checkpoint blockade. Programmed cell death protein
1 (PD-L1) blockade on the tumor cell or PD1 blockade targeting the T
cell is emerging as one of the most powerful strategies to enhance T-cell
eﬀectiveness against cancer [90]. Antibodies or blocking molecules
have been developed targeting the key checkpoint inhibitors. Most
experience with these agents comes from the ﬁeld of solid tumor
immunotherapy [91–93]. However, anti-cytotoxic T lymphocyte
antigen-4 (CTLA-4) has been used in a preclinical AML model [51]
and also for treatment of patients with post-HSCT relapse [94]. This
study demonstrated that CTLA-4 inhibition with ipilimumab does not
increase the risk of GvHD, even in patients who received DLI in
conjunction [95]. While promising responses were achieved, the study
was too small to clearly identify eﬃcacy of the agent in AML. Ongoing
trials are testing the safety and eﬃcacy of CTLA-4 blockade in both
post-transplant relapse settings and nontransplant settings
[ClinicalTrials. gov identiﬁer: NCT00060372, NCT01757639,
NCT01822509]. Similarly, preclinical data for PD-1/ PD-L1 blockade
have shown that the target has therapeutic potential in leukemia [96].
PD-1/PD-L1 blockade has been tested and actively investigated in
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various hematologic malignancies [97] [ClinicalTrials.gov identiﬁer:
NCT02117219, NCT01953692, NCT02332980], but clinical
experiences in AML remain limited. In a phase I study of anti-PD-1
antibody for hematologic malignancies that enrolled total 17 patients, 8
patients had AML [98]. None of the patients experienced toxicity
attributable to the agent. Majority of them did not show any response,
except for one patient who demonstrated marked reduction in
peripheral blood blasts burden. The result suggests that PD-1/PD-L1
blockade can be eﬀective in a selected setting. While checkpoint
inhibition is a promising novel treatment, further studies are
required to understand the most eﬃcacious methods of
administration to exploit the possible clinical beneﬁt. In a recent
study by Davids et al., the immune checkpoint blockade established
by targeting CTLA-4 with ipilimumab was examined in patients after
allo-HSCT. Their early-phase data showed that administration of
ipilimumab was feasible in patients with recurrent hematologic
cancers after allo-HSCT, although immune-mediated toxic eﬀects and
GvHD occurred. Durable responses were observed in association with
several histologic subtypes of these cancers, including extramedullary
acute myeloid leukemia [99].
6.1.2.4. Immunomodulatory drugs (IMiDs). Because lenalidomide
induces morphological and cytogenetic remissions in MDS patients,
including those with excess of blasts, eﬃcacy in AML was expected and
evaluated. In a phase II trial by Chen et al., the eﬃcacy and safety of
lenalidomide in patients with relapsed/refractory AML (n =18) and
high-risk MDS (n =9) with chromosome 5 abnormalities was assessed
[100]. Eighteen adults with AML and 9 with high-risk MDS were
enrolled. Lenalidomide was given orally at doses 5–25 mg daily for 21
days of a 28-d cycle until disease progression or unacceptable adverse
event. Median age for all 27 patients was 64 years. Two patients (7%)
with AML and 5q deletion and +8 cytogenetic abnormalities in 2
separate clones achieved CR or CR without platelet recovery (CRp).
Response durations were 4 and 6 months, respectively. No responses
were seen in patients with chromosome 5 abnormality in a complex
cytogenetic background. Thus, activity of lenalidomide was limited to
patients with noncomplex cytogenetics.
Recently, it was shown that increased miR-181a expression was
associated with improved outcomes in CN-AML. Lenalidomide treat-
ment enhances the C/EBPα-p30 protein levels (which correlates with a
favorable chemotherapy response) and in turn miR-181a which
appears to sensitize AML blasts to chemotherapy [101].
7. Conclusions
AML is a complex disease with a diverse genetic landscape. The
ﬁeld is rapidly expanding with increased understanding of the patho-
physiology. Although allogeneic stem cell transplant has been tradi-
tionally considered to be the best strategy in this setting, the available
data suggest that it may not be the most eﬀective strategy to eradicate
minimal residual disease. Novel agents such as molecularly targeted
drugs (FLT3 or IDH inhibitors) or monoclonal antibody–based agents
including antibody-drug conjugates and bispeciﬁc antibodies, and,
potentially, checkpoint inhibitors and chimeric antigen receptor T
cells, may improve therapeutic strategies to eradicate persistent mini-
mal residual disease remaining after cytotoxic regimens or will be used
to ”bridge” to transplant.
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